Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927020 | 1.00 | MAPT (0.55) | MAPTKMT2ALMNAMEN1HTT | |
| SCHEMBL6695821 | 1.00 | MAPT (0.55) | MAPTKMT2ALMNAMEN1HTT | |
| SCHEMBL6769183 | 0.91 | ALDH1A1 (0.55) | MAPTKMT2ALMNAMEN1HTT | |
| SCHEMBL5820791 | 0.91 | RAB9A (0.62) | MAPTKMT2ALMNAMEN1HTT | |
| SCHEMBL6763984 | 0.91 | MAPT (0.55) | MAPTKMT2ALMNAMEN1HTT | |
| SCHEMBL6763989 | 0.91 | MAPT (0.55) | MAPTKMT2ALMNAMEN1HTT | |
| SCHEMBL6769185 | 0.91 | ALDH1A1 (0.55) | MAPTKMT2ALMNAMEN1HTT | |
| SCHEMBL6761435 | 0.90 | CA1 (0.47) | MAPTKMT2ALMNAMEN1HTT | |
| SCHEMBL6761436 | 0.90 | CA1 (0.47) | MAPTKMT2ALMNAMEN1HTT | |
| SCHEMBL5808255 | 0.90 | MAOA (0.46) | MAPTKMT2ALMNAMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11421108-B2 | Curable organopolysiloxane compositions | WACKER CHEMIE AG (DE) | 2022-08-23 | — | — | US | disclosed |
| EP-3642284-B1 | CURABLE ORGANOPOLYSILOXANE COMPOSITIONS | WACKER CHEMIE AG (DE) | 2022-06-01 | — | — | EP | disclosed |
| EP-3984991-A1 | METHOD FOR SYNTHESIZING ATORVASTATIN CALCIUM INTERMEDIATE BY USING MULTI-COMPONENT ONE-POT METHOD | Zhejiang Hongyuan Pharma Co., Ltd (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-20200325337-A1 | CURABLE ORGANOPOLYSILOXANE COMPOSITIONS | WACKER CHEMIE AG (DE) | 2020-10-15 | — | — | US | disclosed |
| WO-2020016903-A1 | AN IMPROVED AND COMMERCIALLY VIABLE PROCESS FOR PREPARATION OF PYRROLE DERIVATIVES WITH IMPROVED IMPURITY PROFILE & MINIMISATION OF UNIT OPERATIONS. | ARCH PHARMALABS LIMITED (IN) | 2020-01-23 | — | — | WO | disclosed |
| US-8163959-B2 | Reacting 2-halo-1-(4-fluorophenyl)-2-phenone of formula II with 4-methyl-3-oxo-N-phenylpentamide; high purity and good yield; for the synthesis of atorvastatin | ARCH PHARMALABS LIMITED (IN) | 2012-04-24 | — | — | US | disclosed |
| US-20110124704-A1 | DEUTERIUM-ENRICHED ATORVASTATIN | PROTIA, LLC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110060164-A1 | Reacting 2-halo-1-(4-fluorophenyl)-2-phenone of formula II with 4-methyl-3-oxo-N-phenylpentamide; high purity and good yield; for the synthesis of atorvastatin | ARCH PHARMALABS LIMITTED (IN) | 2011-03-10 | — | — | US | disclosed |
| US-7872154-B2 | Method for the preparation of 4-fluoro-α-[2-methyl-1-oxopropyl]-y-oxo-n-β-diphenylbenzenebutanamide and products therefrom | ARCH PHARMALABS LIMITED (IN) | 2011-01-18 | — | — | US | disclosed |
| US-7872154-B2 | Method for the preparation of 4-fluoro-α-[2-methyl-1-oxopropyl]-y-oxo-n-β-diphenylbenzenebutanamide and products therefrom | ARCH PHARMALABS LIMITED (IN) | 2011-01-18 | — | — | US | disclosed |
| US-7745480-B2 | Deuterium-enriched atorvastatin | PROTIA, LLC (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745480-B2 | Deuterium-enriched atorvastatin | PROTIA, LLC (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090298907-A1 | METHOD FOR THE PREPARATION OF 4-FLUORO-ALPHA-[2-METHYL-1-OXOPROPYL]-y-OXO-N-BETA-DIPHENYLBENZENEBUTANAMIDE AND PRODUCTS THEREFROM | ARCH PHARMALABS LIMITED (IN) | 2009-12-03 | — | — | US | disclosed |
| US-20090298907-A1 | METHOD FOR THE PREPARATION OF 4-FLUORO-ALPHA-[2-METHYL-1-OXOPROPYL]-y-OXO-N-BETA-DIPHENYLBENZENEBUTANAMIDE AND PRODUCTS THEREFROM | ARCH PHARMALABS LIMITED (IN) | 2009-12-03 | — | — | US | disclosed |
| WO-2009084827-A2 | SYNTHETIC INTERMEDIATES, PROCESS FOR PREPARING PYRROLYLHEPTANOIC ACID DERIVATIVES THEREFROM | DONG-A PHARM.CO., LTD. (KR) | 2009-07-09 | — | — | WO | disclosed |
| US-20080280971-A1 | deuterated (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid, used for the treatment of dyslipidemia and/or hyperlipemia | PROTIA, LLC (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080280970-A1 | DEUTERIUM-ENRICHED ATORVASTATIN | PROTIA, LLC | 2008-11-13 | — | — | US | disclosed |
| US-20080280971-A1 | deuterated (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid, used for the treatment of dyslipidemia and/or hyperlipemia | PROTIA, LLC (US) | 2008-11-13 | — | — | US | disclosed |
| US-7323490-B2 | Pyrrole compounds and uses thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280971-A1 | deuterated (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid, used for the treatment of dyslipidemia and/or hyperlipemia | PCSK9, DHCR7, HMGCR | MAPT 4315/4885KMT2A 2435/4885LMNA 1000/4885 |
| US-20090298907-A1 | METHOD FOR THE PREPARATION OF 4-FLUORO-ALPHA-[2-METHYL-1-OXOPROPYL]-y-OXO-N-BETA-DIPHENYLBENZENEBUTANAMIDE AND PRODUCTS THEREFROM | NEFM, BPGM, HADHB | MAPT 2683/4885KMT2A 1045/4885LMNA 1916/4885 |
| US-20110124704-A1 | DEUTERIUM-ENRICHED ATORVASTATIN | HMGCR, PCSK9, STARD3 | MAPT 2590/4885KMT2A 2262/4885LMNA 2028/4885 |
| US-20110060164-A1 | Reacting 2-halo-1-(4-fluorophenyl)-2-phenone of formula II with 4-methyl-3-oxo-N-phenylpentamide; high purity and good yield; for the synthesis of atorvastatin | HMGCR, TGFB1, HSD17B12 | MAPT 2352/4885KMT2A 1222/4885LMNA 734/4885 |
| US-20080280970-A1 | DEUTERIUM-ENRICHED ATORVASTATIN | HMGCR, PCSK9, STARD3 | MAPT 2590/4885KMT2A 2262/4885LMNA 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.